Sponsored by News
Major study shows new insights into lasting impacts of COVID-19
Tens of thousands of people in England may have lasting symptoms from COVID-19 more than a year after infection, new analysis reveals. The findings, published in Nature Communications, come from a representative sample of more than a quarter of a million people in England surveyed as part of the REACT study, who self-reported their symptoms and the impact of COVID-19 on their health and quality of life. The work, led by researchers at Imperial College London, finds that while the vast majority of people recovered from infection within two weeks, a significant proportion of the group (7.5%) reported persistent symptoms lasting 12 weeks or more (Long COVID), and 5% reported symptoms lasting more than a year. The most common lasting symptoms were mild fatigue, difficulty thinking or concentrating and joint pains. But other persistent symptoms reported included loss or change of sense of smell or taste, shortness of breath, severe fatigue, chest tightness or pain, and poor memory. People were more likely to report symptoms for a long time after their initial infection if they were female, had severe initial symptoms, were infected earlier in the pandemic, or had pre-existing health conditions. Some of these symptoms were also quite often reported by people who did not have previous COVID-19. However, mental health and health-related quality of life were worse among participants with ongoing persistent symptoms
post-COVID compared with those who had never had COVID-19 or had recovered. According to the researchers, the analysis
provides a snapshot of the continued impact of COVID-19 in the UK. They highlight that while SARS-CoV-2 infections are typically short duration, a significant proportion of adults will continue to experience persistent illness (Long COVID) that in some cases may last for over a year or more. But they highlight that a sizeable proportion still fully recover after a prolonged period. Professor Paul Elliott, Chair in Epidemiology and
Public Health Medicine from the School of Public Health at Imperial College London, said: “Our latest findings from the REACT study offer further insights into the underlying factors which are associated with prolonged symptoms after initial COVID-19. We find that the variant of SARS-CoV-2 people are infected with, the initial severity of their symptoms, and whether they have pre-existing health conditions all have an impact on whether they will develop lasting symptoms.” In the latest analysis, the team collected follow
up survey responses from 276,840 adults in England who registered for the REACT study. Of these, 59% reported testing positive for COVID-19 between 2020 and 2022. Analysis shows the average duration of
symptomatic illness was around 10 days, but 1 in 10 people in the study reported symptoms for more than 4 weeks, 1 in 13 for more than 12 weeks, and 1 in
20 for more than a year. The analysis showed that almost a third of people reporting symptoms at 12 weeks will have recovered within a year. Among those whose lasting symptoms had fully resolved, people reported health status similar to those with shorter recovery, or who had never had COVID-19. According to the researchers, analysis also
shows that people infected in the Omicron wave of the pandemic were 88% less likely to experience symptoms longer than 4 weeks post-infection, compared to earlier waves. Dr. Christina Atchison, Principal Clinical Academic
Fellow within the School of Public Health and first author on the study, said: “While the landscape has changed considerably since the early peak of the COVID-19 pandemic, this analysis shows that a proportion of adults are still experiencing lasting symptoms. Importantly, we find that compared to wild type virus, those infected when Omicron was dominant were far less likely to report symptoms lasting beyond 12 weeks. This may reflect the changing levels of immunity in the population from previous exposure to the virus and vaccination.”
Wipe out infections, without wiping out your equipment.
Protect & Prevent with #PurpleTop
The first "Made in Britain" 2-in-1 cleaning & disinfectant wipe included in more than 700 manufacturers IFUs
Request Samples via
contact@pdi-emea.com T: + 44 (0) 8081 697 945
W:
pdi-intl.com
PDI International
December 2023 I
www.clinicalservicesjournal.com 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
